This topic contains a solution. Click here to go to the answer

Author Question: In a graph of the results from multiple-baseline design using two participants, which feature ... (Read 119 times)

Davideckstein7

  • Hero Member
  • *****
  • Posts: 555
In a graph of the results from multiple-baseline design using two participants, which feature justifies a conclusion that the treatment causes changes in behavior?
 
  a. the size of the change in behavior each time the treatment is introduced
 b. the time delay between the introduction of the treatment and the first change in behavior for each participant
  c. the return to baseline behavior when the treatment is withdrawn for both participants
 d. demonstrating that the same change in behavior occurs when the treatment is introduced at different times for the participants

Question 2

In GLM equations, the letter z stands for the ____.
 
  a. outcome score
 b. error
 c. dummy variable
  d. predictor score



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

ultraflyy23

  • Sr. Member
  • ****
  • Posts: 312
Answer to Question 1

d

Answer to Question 2

c




Davideckstein7

  • Member
  • Posts: 555
Reply 2 on: Jun 19, 2018
Excellent


ultraflyy23

  • Member
  • Posts: 312
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

When blood is deoxygenated and flowing back to the heart through the veins, it is dark reddish-blue in color. Blood in the arteries that is oxygenated and flowing out to the body is bright red. Whereas arterial blood comes out in spurts, venous blood flows.

Did you know?

All adults should have their cholesterol levels checked once every 5 years. During 2009–2010, 69.4% of Americans age 20 and older reported having their cholesterol checked within the last five years.

Did you know?

There are approximately 3 million unintended pregnancies in the United States each year.

Did you know?

It is believed that humans initially contracted crabs from gorillas about 3 million years ago from either sleeping in gorilla nests or eating the apes.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library